EDIT - エディタス・メディシン (Editas Medicine Inc.) エディタス・メディシン

 EDITのチャート


 EDITの企業情報

symbol EDIT
会社名 Editas Medicine Inc (エディタス・メディシン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エディタス・メディシン(Editas Medicine Inc.)はゲノム編集会社である。同社は、疾患の原因となる遺伝子を編集することによって、遺伝子疾患を有する患者を治療する。同社はゲノム編集技術分野での開発と商品化を通じて事業を展開する。同社はクラスター化され、規則的に間隔を置いて配置された短いパリンドローム反復(CRISPR)技術に基づくゲノム編集プラットフォームを開発している。CRISPRは、CRISPR関連タンパク質9(Cas9)またはPrevotellaおよびFrancisella 1(Cpf1)由来のCRISPRのいずれかを含む酵素からなるタンパク質 - リボ核酸(RNA)複合体を使用し、特定のデオキシリボ核酸(DNA)配列を認識するように設計されたガイドRNA分子に結合する。同社のプラットフォームは、ヌクレアーゼエンジニアリング、デリバリー、コントロールと特異性、指示編集の4つのコンポーネントから構成される。同社のプログラムには、眼疾患、免疫腫瘍学のための人工T細胞療法、および追加の研究プログラムが含まれる。同社はLeber先天性アメロシスタイプ10(LCA10)のゲノム編集治療薬を開発している。   エディタス・メディシンは米国のライフサイエンス企業。病原性遺伝子ゲノム編集により、遺伝子関連疾患を治療する。ゲノム編集プラットフォ―ム「CRISPR/Cas9」を商標登録し、特定のDNAを認識し削除した後ゲノム配列を編集する技術を開発。同社プラットフォ―ムにはヌクレア―ゼ、送達システム、ゲノム編集などを含む。本社はマサチュ―セッツ州ケンブリッジ。  
本社所在地 11 Hurley Street Cambridge MA 02141 USA
代表者氏名 James C. Mullen ジェームスC.ミューレン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-401-9000
設立年月日 41518
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 112人
url www.editasmedicine.com
nasdaq_url https://www.nasdaq.com/symbol/edit
adr_tso
EBITDA EBITDA(百万ドル) -131.47100
終値(lastsale) 27.88
時価総額(marketcap) 1329196954.72
時価総額 時価総額(百万ドル) 1323.476
売上高 売上高(百万ドル) 21.24800
企業価値(EV) 企業価値(EV)(百万ドル) 112.34
当期純利益 当期純利益(百万ドル) -132.45000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Editas Medicine Inc revenues increased from $3.8M to $11.3M. Net loss increased 21% to $69.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 56% to $46.1M (expense) General and administrative - Balancing increase of 14% to $22.9M (expense).

 EDITのテクニカル分析


 EDITのニュース

   Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson Sells 1,568 Shares of Stock  2021/01/14 11:44:57 Watchlist News
Editas Medicine, Inc. (NASDAQ:EDIT) CFO Michelle Robertson sold 1,568 shares of Editas Medicine stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $78.27, for a total transaction of $122,727.36. Following the sale, the chief financial officer now directly owns 18,432 shares of the company’s stock, […]
   Editas Medicine's science head Albright leaves for new job just as biotech gets trial clearance for sickle cell therapy  2021/01/11 16:11:12 Endpoints News
Editas Medicine has received the FDA’s blessing to enter the clinic with its first ex vivo cell therapy — but it will do so without CSO Charles Albright, who is leaving his post for the same gig at an early-stage company. The FDA clearance was announced minutes after Editas shared
   Covid-19 Impact On CRISPR and CAS Gene Market Swot Analysis by Key Players: Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific  2021/01/11 13:36:57 OpenPR
COHERENT MARKET INSIGHTS has added a new report titled Global CRISPR and CAS Gene Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. This CRISPR and CAS Gene Market
   Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial - Stocks News Feed  2021/01/11 11:02:00 Stocks News Feed
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the U.S. Food and Drug Administration (FDA) has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin dosing patients. The Company is required to develop and… Read More »Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical Trial
   Study Describes New Way to Place CRISPR/Cas9 Into Cancer Cells, Can Industry Giants take advantage of this Advancement? | Key PLayers: Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences  2021/01/07 06:47:59 OpenPR
Clusters of regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 nuclease (Cas9) is an innovative genome editing tool that has recently changed the field of human genetic engineering. CRISPR/Cas9 can regulate gene expression in plants, humans, and animals based on
   Editas Medicine Announces Third Quarter 2020 Results and Update  2020/11/05 21:02:00 GlobeNewswire
EDIT-101 for LCA10 ‒ BRILLIANCE trial adult low-dose cohort completed EDIT-301 for sickle cell disease ‒ on track for IND filing by end of 2020 EDIT-201…
   Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update  2020/10/29 20:01:00 GlobeNewswire
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will…
   Editas Medicine Inc (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages  2020/10/24 00:44:41 US Banking News
Shares of Editas Medicine Inc (NASDAQ:EDIT) have received a consensus recommendation of “Hold” from the ten research firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among […]
   Editas Medicine Inc (NASDAQ:EDIT) Receives Average Recommendation of “Hold” from Brokerages  2020/10/23 22:44:47 Daily Political
Shares of Editas Medicine Inc (NASDAQ:EDIT) have received an average recommendation of “Hold” from the ten research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that […]
   Editas Medicine (NASDAQ:EDIT) Trading Up 6.6%  2020/10/22 19:18:41 US Banking News
Editas Medicine Inc (NASDAQ:EDIT)’s stock price traded up 6.6% during mid-day trading on Thursday . The stock traded as high as $32.33 and last traded at $32.26. 774,121 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 963,448 shares. The stock had previously closed at $30.27. EDIT has […]
   Editas Medicine Announces Third Quarter 2020 Results and Update  2020/11/05 21:02:00 GlobeNewswire
EDIT-101 for LCA10 ‒ BRILLIANCE trial adult low-dose cohort completed EDIT-301 for sickle cell disease ‒ on track for IND filing by end of 2020 EDIT-201…
   Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate Update  2020/10/29 20:01:00 GlobeNewswire
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will…
   Editas Medicine Inc (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages  2020/10/24 00:44:41 US Banking News
Shares of Editas Medicine Inc (NASDAQ:EDIT) have received a consensus recommendation of “Hold” from the ten research firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among […]
   Editas Medicine Inc (NASDAQ:EDIT) Receives Average Recommendation of “Hold” from Brokerages  2020/10/23 22:44:47 Daily Political
Shares of Editas Medicine Inc (NASDAQ:EDIT) have received an average recommendation of “Hold” from the ten research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that […]
   Editas Medicine (NASDAQ:EDIT) Trading Up 6.6%  2020/10/22 19:18:41 US Banking News
Editas Medicine Inc (NASDAQ:EDIT)’s stock price traded up 6.6% during mid-day trading on Thursday . The stock traded as high as $32.33 and last traded at $32.26. 774,121 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 963,448 shares. The stock had previously closed at $30.27. EDIT has […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エディタス・メディシン EDIT Editas Medicine Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)